EM-T3Expert Opinion on Drug Safety2023-02-01第 22 卷第 2 期，175-181开放获取高影响力 · 前 10%
Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system
